AI legitimacy and cure approvals advance in parallel

Global active cure-related trials are now at 21,269, while, in the same 24-hour window, the Wire logged 47 new signals and Cure research added 28 new entries. On the AI side, the Wire’s top control thread is legitimacy: ABC reports Australia’s copyright law may not need changes, shifting the dispute from legislation to trust; separately, capacity is becoming a bottleneck discussion as Nokia’s CEO says data centers could be built twice as fast if supply loosens. In life sciences, the Cure feed delivered immediate translational momentum: Lilly’s Jaypirca (pirtobrutinib) received FDA approval as first-line therapy for previously untreated chronic lymphocytic leukemia, alongside Phase 3 pneumococcal vaccine progress from Vaxcyte that strengthens near-term competitive positioning. Together, these signals suggest the window for coordinated progress—through both better AI governance and faster medical deployment—is still open, even as operational disruption and infrastructure constraints remain active variables. The window is still open.